ABOUT MAXCYTE, INC.

MaxCyte® stands at the forefront of cell-engineering, providing the leading non-viral transfection platform powered by our Flow Electroporation® technology, that is instrumental in the discovery and commercialization of cutting-edge cell-based therapies. In 2024, our ExPERT electroporation platform is the only proven transfection technology supporting a commercialized non-viral cell therapy. Coupled with our unparalleled scientific, technical and regulatory support, we enable the complex engineering required for the creation of innovative cell therapies. As a trailblazer in this field for 25 years, we are committed to transforming the future of medicine and helping improve patient outcomes. Let MaxCyte be your partner in navigating the exciting landscape of cell therapy development.

MAXCYTE E-BOOKS

  • MaxCyte's electroporation platform accelerates therapeutic antibody development with scalable, high-efficiency transfection, enabling rapid transient protein expression, and IND-enabling studies in weeks.

  • Induced pluripotent stem cells (iPSCs) hold great potential for disease modeling, personalized medicine, and regenerative therapies. Explore electroporation technology and the various research projects it is being used in.

  • This collection of articles explores the role of genetic engineering in understanding, preventing, and treating genetic diseases.

  • This collection of articles discusses the development of cancer immunotherapies through cutting-edge genome engineering and sophisticated strategies.